NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.99 -0.37 (-0.44%) GOLD FUTURES
2,334.80 -7.30 (-0.31%) DOW
38,486.60 -17.09 (-0.04%) Bitcoin GBP
51,621.05 -1,816.69 (-3.40%)
Citius Pharmaceuticals, Inc. (CTXR)
| Previous close | 0.7673 |
| Open | 0.7700 |
| Bid | 0.6922 x 200 |
| Ask | 0.7260 x 200 |
| Day's range | 0.7000 - 0.7701 |
| 52-week range | 0.6000 - 1.5600 |
| Volume | |
| Avg. volume | 840,640 |
| Market cap | 112.957M |
| Beta (5Y monthly) | 1.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2600 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCitius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the University of Minnesota Masonic Cancer Center intends to expand their ongoing investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox) in combination with FDA-approved CAR-T products for the treatment of B-cell lymphomas. The ongoing study, led by Dr. Veronika Bachanova at the U
- PR Newswire
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the 14th Annual LD Micro Invitational investor conference being held April 8-9, 2024, in New York City.
- PR Newswire
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Company's Biologics License Application (BLA) for LYMPHIR™ (denileukin diftitox), an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma
